IRIDEX (NASDAQ:IRIX) Earns Hold Rating from Analysts at StockNews.com

Analysts at StockNews.com assumed coverage on shares of IRIDEX (NASDAQ:IRIX) in a research note issued to investors on Sunday. The firm set a “hold” rating on the medical equipment provider’s stock.

IRIDEX Stock Performance

NASDAQ IRIX opened at $1.65 on Friday. The business’s 50-day moving average price is $1.70 and its 200 day moving average price is $1.81. IRIDEX has a twelve month low of $1.27 and a twelve month high of $3.65. The company has a market capitalization of $27.45 million, a PE ratio of -2.46 and a beta of 0.82. The company has a current ratio of 1.54, a quick ratio of 0.85 and a debt-to-equity ratio of 0.55.

IRIDEX (NASDAQ:IRIX) last released its earnings results on Tuesday, November 12th. The medical equipment provider reported ($0.12) earnings per share for the quarter. The business had revenue of $11.58 million for the quarter. IRIDEX had a negative return on equity of 192.95% and a negative net margin of 22.79%. During the same quarter in the previous year, the business earned ($0.11) EPS.

IRIDEX Company Profile

IRIDEX Corporation, an ophthalmic medical technology company, provides therapeutic based laser systems, delivery devices, and consumable instrumentation to treat sight-threatening eye diseases in ophthalmology. It offers laser consoles, such as Cyclo G6 laser system for use in the treatment of glaucoma; IQ 532 and IQ 577 laser systems, which are used for the treatment of retinal disorders; and OcuLight TX, OcuLight SL, OcuLight SLx, OcuLight GL, and OcuLight GLx laser photocoagulation systems that are used to treat proliferative diabetic retinopathy, macular holes, retinal tears, and detachments.